中国医学装备
中國醫學裝備
중국의학장비
CHINA MEDICAL EQUIPMENT
2014年
7期
96-98
,共3页
生物共振仪%儿童%支气管哮喘%效果
生物共振儀%兒童%支氣管哮喘%效果
생물공진의%인동%지기관효천%효과
Bioresonnance device%Children%Bronchial asthma%Efficacy
目的：探讨生物共振仪治疗儿童支气管哮喘的有效性和复发情况。方法：选取进行生物共振治疗的支气管哮喘患儿55例，随机分为两组(疗程为6月以内组25例和疗程为6月以上组30例)。所有患儿均接受每周一次生物共振治疗，必要时应用治疗性药物如糖皮质激素、白三烯调节剂及β2受体激动剂和茶碱等。治疗前及疗程结束时各测一次呼气峰流速，并观察2年内的复发情况。结果：生物共振仪治疗后，两组患儿的最大呼气流量(PEFR)均明显提高。6月以内组和6月以上组的峰值呼气流速(PEF)变化值分别由(68.00±3.14)%和(69.95±4.74)%上升至(86.92±3.59)%和(91.62±2.84)%。2年内6月以内组患儿有10例复发，复发率为40%；6月以上组患儿有3例复发，复发率为10%。结论：支气管哮喘患儿应尽早进行生物共振与药物联合治疗，以缓解症状降低复发率。
目的：探討生物共振儀治療兒童支氣管哮喘的有效性和複髮情況。方法：選取進行生物共振治療的支氣管哮喘患兒55例，隨機分為兩組(療程為6月以內組25例和療程為6月以上組30例)。所有患兒均接受每週一次生物共振治療，必要時應用治療性藥物如糖皮質激素、白三烯調節劑及β2受體激動劑和茶堿等。治療前及療程結束時各測一次呼氣峰流速，併觀察2年內的複髮情況。結果：生物共振儀治療後，兩組患兒的最大呼氣流量(PEFR)均明顯提高。6月以內組和6月以上組的峰值呼氣流速(PEF)變化值分彆由(68.00±3.14)%和(69.95±4.74)%上升至(86.92±3.59)%和(91.62±2.84)%。2年內6月以內組患兒有10例複髮，複髮率為40%；6月以上組患兒有3例複髮，複髮率為10%。結論：支氣管哮喘患兒應儘早進行生物共振與藥物聯閤治療，以緩解癥狀降低複髮率。
목적：탐토생물공진의치료인동지기관효천적유효성화복발정황。방법：선취진행생물공진치료적지기관효천환인55례，수궤분위량조(료정위6월이내조25례화료정위6월이상조30례)。소유환인균접수매주일차생물공진치료，필요시응용치료성약물여당피질격소、백삼희조절제급β2수체격동제화다감등。치료전급료정결속시각측일차호기봉류속，병관찰2년내적복발정황。결과：생물공진의치료후，량조환인적최대호기류량(PEFR)균명현제고。6월이내조화6월이상조적봉치호기류속(PEF)변화치분별유(68.00±3.14)%화(69.95±4.74)%상승지(86.92±3.59)%화(91.62±2.84)%。2년내6월이내조환인유10례복발，복발솔위40%；6월이상조환인유3례복발，복발솔위10%。결론：지기관효천환인응진조진행생물공진여약물연합치료，이완해증상강저복발솔。
Objective:To evaluate efficacy and recurrence of bioresonnance therapy in children with bronchial asthma. Methods: Fifty-five children with asthma by bioresonnance therapy were randomly divided into two groups include within six-month group, and above six-month group according to the course of treatment. All patients received bioresonnance therapy once a week, they used therapeutic medicines include corticosteroids, LTRA, β2-agonists, and theophylline when necessary. The peak expiratory flow rate(PEFR)was measured at the time of pre-treatment and post-treatment, and observed recurrence rate in two years. Results:The PEFR value of the two groups improved evidently post-treatment. The PEFR value of the within six-month group, and the above six-month group rose from 68.00±3.14, 69.95±4.74 to 86.92±3.59, 91.62±2.84.10 patients recurred in the within six-month group, which accounted for 40.00% in two years;3 patients recurred in the above six-month group, which accounted for 10.00% in two years. Conclusion: Children with bronchial asthma should be treated by bioresonance and medicines together as early as possible, which could relieve symptoms and reduce recurrence rate.
